Namenda Fact Sheet
Forest Labs; market exclusivity expires 2008
Moderate to severe Alzheimer’s dementia.
- Off-label use for mild to moderate dementia.
NMDA antagonist, works by preventing too much glutamate from damaging neurons.
- 5 mg tan and 10 mg gray tablets
- 2 mg/mL oral solution
- Start at 5 mg QD for 1 week, then 5 mg BID for 1 week, then 10 mg QAM and 5 mg QPM for 1 week, and finally 10 BID (target dose).
- No dose adjustment needed in hepatic impairment; decrease dose in severe renal impairment.
Most common: dizziness, sedation, transient confusion.
- Pregnancy risk category B.
No significant interactions reported.
Metabolized partly by liver; half is excreted unchanged in the urine.
Namenda mildly augments the effects of Aricept in clinical trials (JAMA 2004;291:317-324).
- Probably less effective for mild dementia; this indication was rejected by the FDA in 2005.
Earn CME Credit Instantly!
Not quite ready for a one-year subscription to The Carlat Psychiatry Report? Need CME credits on a particular topic or on a tight deadline?
Try our A la Carte CME! You can buy single or multiple credits of continuing education, without committing to a year-long newsletter subscription.
Already an A la Carte subscriber? Click here to go to your a la carte page
Steve Balt Interviewed by NPR
Our own Steve Balt was interviewed on NPR's "Talk of the Nation" on psychiatry's shift toward drugs and away from talk therapy.
After 10 years at the helm of TCPR, Dr. Carlat has handed over editor-in-chief duties to Dr. Steve Balt. We’re excited to welcome him aboard! Read More...
The 2012 Carlat Atypical Antipsychotics Table is Now Available!
With all the atypicals on the market, it's hard to keep track of indications, dosages, and all the other relevant facts for each drug. Use this table for summaries on these meds, their uses, their side effects, and a whole slew of other information.
TCPR Continuing Education